Dallas, TX (PRWEB) March 10, 2014
According to IDF (the International Diabetes Federation), incidence of diabetes among adults aged 20-79 in the world was 8.3% in 2013 with more than 380 million patients worldwide.
On December 26, 2001 Novo Nordisk announced that the first insulin analogue insulin aspart (marketed by Novo Nordisk with the trade name "Novorapid") to treat insulin pump was approved by FDA. Insulin aspart was created through recombinant DNA technology so that the amino acid, B28, which is normally proline, is substituted with an aspartic acid residue. The sequence was inserted into the yeast genome, and the yeast expressed the insulin analog, which was then harvested from a bioreactor. This analog has increased charge repulsion, which prevents the formation of hexamers, to create faster-acting insulin. Insulin aspart can reduce the level of postprandial glucose and glycated hemoglobin A (HbA1c). The onset of action is approximately 10 to 20 minutes. The global sales revenue of Novorapid in 2012 reached USD 2.78 billion, increased by 20% YOY. In April 2005, the first premixed insulin analogue Novomix 30 (composed of 30% soluble insulin aspart and 70% insulin aspart protamine) was launched in China.
Complete report on Insulin Aspart Market available @ http://www.chinamarketresearchreports.com/114745.html . Or Purchase this report @ http://www.chinamarketresearchreports.com/contacts/purchase.php?name=114745 .
Rapid economic growth in the last 30 years has changed Chinese people's eating habits and led to less physical activities. Incidence of diseases related to obesity keeps increasing. In China 40% of the youth aged 18-29 are potential diabetes patients with a higher risk of stroke, heart disease and renal failure. By the end of 2013 there were about 98 to 120 million diabetes patients in China. The market size of diabetes drugs is also increasing.
According to IDF (the International Diabetes Federation), incidence of diabetes among adults aged 20-79 in the world was 8.3% in 2013 with 382 million patients worldwide. The number of diabetes patients in China was more than 98 million, ranking the first in the world. The rapid growth of diabetes patients is becoming a serious economic and social issue in China and other developing countries.
The first ultra-short-acting human insulin analogue insulin lispro (produced by Eli Lilly and Company with the trade name "Humalog") was launched in 1996 and approved by FDA. Insulin lispro is a fast acting insulin analogue with one primary advantage over regular insulin for postprandial glucose control. It has a shortened delay of onset, allowing slightly more flexibility than regular insulin, which requires a longer waiting period before starting a meal after injection. In 2012, global sales revenue of Humalog reached nearly USD 2.4 billion.
Humalog was launched in China in 2005 and its annual sales revenue continues to grow rapidly. According to CRI's investigation on certain Chinese sample hospital market, the sales revenue of insulin lispro in Chinese hospitals grew more than 100 times from 2005 to 2013. Most of the market is occupied by Eli Lilly and Company while the other belongs to Gan & Lee Pharmaceuticals. There used to be legal disputes between the two companies over the patent of insulin lispro in China. Based on investigation, insulin lispro produced by other Chinese enterprises will soon appear on the market.
Incidence of diabetes continues to rise in China as life improves and lifestyle changes. IDF predicts that the number of diabetes patients in China will reach 143 million in 2035, which is still top of the world. Since market size of insulin lispro is growing rapidly in China, huge potential exists in the market.
Complete report on Insulin Lispro Market available @ http://www.chinamarketresearchreports.com/114746.html . Or Purchase this report @ http://www.chinamarketresearchreports.com/contacts/purchase.php?name=114746 .
Browse more reports on Life Sciences Industry @ http://www.chinamarketresearchreports.com/cat/life-sciences.html .
ChinaMarketResearchReports.com is an online database of market research reports offers in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.